ImmunityBio, Inc.IBRXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank33
3Y CAGR-29.5%
5Y CAGR-45.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-29.5%/yr
vs -6.1%/yr prior
5Y CAGR
-45.0%/yr
Recent acceleration
Acceleration
-23.4pp
Decelerating
Percentile
P33
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 9.33% |
| 2024 | -18.17% |
| 2023 | -6.36% |
| 2022 | 26.63% |
| 2021 | 40.46% |
| 2020 | 185.38% |
| 2019 | -8.49% |
| 2018 | 34.29% |
| 2017 | 49.85% |
| 2016 | 132.17% |